What is the recommended dose of N-acetylcysteine (NAC) for acute liver failure in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

N-acetylcysteine (NAC) Dosing in Pediatric Acute Liver Failure

For pediatric acute liver failure, N-acetylcysteine should be administered intravenously with a loading dose of 150 mg/kg over 15-60 minutes, followed by maintenance doses of 50 mg/kg over 4 hours and 100 mg/kg over 16 hours. 1

Indications for NAC in Pediatric Acute Liver Failure

NAC is indicated in the following scenarios:

  • Acetaminophen-induced liver failure: Treatment should be initiated immediately without waiting for serum acetaminophen determinations 2
  • Non-acetaminophen liver failure: NAC is suggested to improve morbidity and mortality 2

Administration Routes and Dosing Protocols

Intravenous Administration (Preferred in Acute Liver Failure)

  • Loading dose: 150 mg/kg over 15-60 minutes
  • First maintenance dose: 50 mg/kg over 4 hours
  • Second maintenance dose: 100 mg/kg over 16 hours 1

Oral Administration (If IV access unavailable)

  • Loading dose: 140 mg/kg (diluted to 5% solution)
  • Maintenance dose: 70 mg/kg every 4 hours for 17 doses 1
  • Oral administration may be contraindicated in patients with gastrointestinal bleeding or worsening mental status

Special Considerations for Children

  • For children with acute liver failure requiring emergency management, initiate NAC immediately at 1 mg/kg/day 2
  • If no improvement is observed or in cases of severe liver failure, the dose can be increased to 2 mg/kg 2
  • If there is no response after approximately 1 week of NAC therapy, consideration for hepatic transplantation should be initiated 2
  • In cases of persistent severe coagulopathy and/or encephalopathy, transplantation considerations may need to begin after only 2-3 days 2

Monitoring During NAC Treatment

  • Monitor for hypersensitivity reactions (occurs in 10-15% of patients)
  • Common side effects include nausea, vomiting, and rarely urticaria or bronchospasm 1
  • Continue NAC treatment beyond the initial protocol if:
    • Liver enzymes remain elevated
    • INR > 2.0
    • Patient is clinically unstable 1

Efficacy Considerations

  • NAC treatment response is usually rapid in acetaminophen-induced liver failure, with urinary SA normalizing after 24 hours and clinical response occurring within 1 week 2
  • For non-acetaminophen liver failure in children, evidence is mixed:
    • Some studies show improved survival with native liver 3
    • However, a placebo-controlled trial found that 1-year liver transplant-free survival was significantly lower with NAC (35%) compared to placebo (53%), particularly among children less than 2 years old 4

Adjunctive Management

  • Intravenous 10% dextrose/normal saline solutions should be administered at 1.5-2.0 times the normal IV fluid maintenance rate for age to maintain normoglycemia 2
  • Consider administration of fresh frozen plasma and vitamin K to correct coagulopathy 2
  • Treatment of metabolic acidosis may be required 2
  • When the patient is clinically stable, introduce a small amount of complete protein (0.25-0.5 mg/kg/day) by 36-48 hours 2

Important Caveats

  • NAC treatment should be initiated as early as possible, as the interval between liver injury and treatment is closely related to outcome 2
  • The benefits of NAC may be limited to patients with early-stage encephalopathy (grades I-II) 2
  • Consultation with a pediatric liver transplant center should be sought for optimal management 2

References

Guideline

Acute Liver Injury Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.